Demant Crescita futura

Future criteri di controllo 3/6

Demant prevede che gli utili e i ricavi cresceranno rispettivamente di 12.4% e 6.1% all'anno. Si prevede che l'EPS crescerà di 15.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 28.1% in 3 anni.

Informazioni chiave

12.4%

Tasso di crescita degli utili

15.5%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	22.6%
Tasso di crescita dei ricavi	6.1%
Rendimento futuro del capitale proprio	28.1%
Copertura analitica	Good
Ultimo aggiornamento	15 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

BATS-CHIXE:DEMANC - Stime future degli analisti e dati finanziari passati (DKK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	25,845	3,453	3,460	4,656	15
12/31/2025	24,035	3,075	3,148	4,202	17
12/31/2024	22,427	2,490	2,699	3,671	15
6/30/2024	22,836	2,535	2,836	3,644	N/A
3/31/2024	22,640	2,544	3,130	3,957	N/A
12/31/2023	22,443	2,552	3,424	4,270	N/A
9/30/2023	21,442	2,577	2,932	3,815	N/A
6/30/2023	20,902	2,488	2,462	3,387	N/A
3/31/2023	20,304	2,381	1,954	2,878	N/A
12/31/2022	19,705	2,274	1,445	2,369	N/A
9/30/2022	19,181	2,460	1,581	2,472	N/A
6/30/2022	18,656	2,645	1,716	2,575	N/A
3/31/2022	18,281	2,671	2,135	2,927	N/A
12/31/2021	17,905	2,696	2,553	3,279	N/A
9/30/2021	17,521	2,453	2,663	3,341	N/A
6/30/2021	17,137	2,209	2,772	3,403	N/A
3/31/2021	15,803	1,665	2,356	3,012	N/A
12/31/2020	14,469	1,121	1,940	2,621	N/A
9/30/2020	14,072	970	1,507	2,226	N/A
6/30/2020	13,674	818	1,073	1,831	N/A
3/31/2020	14,310	1,140	1,228	1,990	N/A
12/31/2019	14,946	1,462	1,383	2,149	N/A
9/30/2019	14,728	1,579	1,218	1,942	N/A
6/30/2019	14,510	1,695	1,052	1,734	N/A
3/31/2019	14,224	1,759	1,059	1,709	N/A
12/31/2018	13,937	1,823	1,065	1,683	N/A
9/30/2018	13,699	1,836	1,268	1,833	N/A
6/30/2018	13,461	1,849	1,471	1,982	N/A
3/31/2018	13,325	1,802	N/A	1,927	N/A
12/31/2017	13,189	1,754	N/A	1,872	N/A
9/30/2017	12,943	1,689	N/A	1,855	N/A
6/30/2017	12,697	1,624	N/A	1,837	N/A
3/31/2017	12,350	1,542	N/A	1,758	N/A
12/31/2016	12,002	1,459	N/A	1,679	N/A
9/30/2016	11,717	1,429	N/A	1,622	N/A
6/30/2016	11,432	1,399	N/A	1,565	N/A
3/31/2016	11,049	1,418	N/A	1,579	N/A
12/31/2015	10,665	1,436	N/A	1,592	N/A
9/30/2015	10,258	1,402	N/A	1,568	N/A
6/30/2015	9,850	1,367	N/A	1,544	N/A
3/31/2015	9,598	1,347	N/A	1,520	N/A
12/31/2014	9,346	1,326	N/A	1,495	N/A
9/30/2014	9,221	1,301	N/A	1,380	N/A
6/30/2014	9,095	1,275	N/A	1,265	N/A
3/31/2014	9,027	1,280	N/A	1,274	N/A
12/31/2013	8,959	1,285	N/A	1,282	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di DEMANC ( 12.4% all'anno) è superiore al tasso di risparmio ( 2.1% ).

Guadagni vs Mercato: Si prevede che gli utili di DEMANC ( 12.4% all'anno) cresceranno più lentamente rispetto al mercato UK ( 14.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di DEMANC cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di DEMANC ( 6.1% all'anno) crescerà più rapidamente del mercato UK ( 3.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DEMANC ( 6.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di DEMANC sarà elevato tra 3 anni ( 28.1 %)

Demant Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Demant A/S Updates Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2023

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Demant A/S Revises Earnings Guidance for the Full Year 2022

Demant A/Sreiterated Guidance for the Year 2021

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2024

Investor sentiment improves as stock rises 21%

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Less than half of directors are independent

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Now 21% undervalued

Demant A/S Announces Executive Changes

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Now 22% undervalued

Less than half of directors are independent

Less than half of directors are independent

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Demant A/S Revises Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Demant A/S Announces Update on Voluntary Field Corrective Action

Less than half of directors are independent

Demant A/Sreiterated Guidance for the Year 2021

Less than half of directors are independent

Less than half of directors are independent

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

New 90-day high: kr.263

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: kr.237

Demant Launches New Flagship Hearing aids

New 90-day high: kr.235

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita